• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: CareDx Inc. filed SEC Form 8-K: Leadership Update

    4/23/26 4:12:41 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    cdna-20260420
    0001217234TRUE00012172342026-04-202026-04-20

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K/A
    (Amendment No. 2)
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): April 20, 2026
    CAREDX, INC.
    (Exact Name of Registrant as Specified in its Charter)
    Delaware
     
    001-36536
     
    94-3316839
    (State or Other Jurisdiction
    of Incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)
    8000 Marina Boulevard
    Brisbane, California 94005
    (Address of Principal Executive Offices) (Zip Code)
    (415) 287-2300
    Registrant’s telephone number, including area code
    N/A
    (Former Name, or Former Address, if Changed Since Last Report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
     Securities registered pursuant to Section 12(b) of the Exchange Act:
    (Title of each class)
    (Trading Symbol)
    (Name of exchange on which registered)
    Common Stock, $0.001 Par Value
    CDNA
    The Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Explanatory Note

    This Current Report on Form 8-K/A (this “Amendment No. 2”) amends the Current Report on Form 8-K filed by CareDx, Inc. (the “Company”) with the Securities and Exchange Commission on February 24, 2026, as amended by Amendment No. 1 on Form 8-K/A filed with the SEC on February 25, 2026 (together, the “Original Report”). This Amendment No. 2 is being filed to supplement the Company’s disclosure under Item 5.02 of the Original Report. The Original Report otherwise remains unchanged.

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    As previously disclosed in the Original Report, on February 24, 2026, the Company appointed Keith Kennedy, the Company’s previous Chief Operating Officer, as the Company’s Chief Financial Officer and Chief Operating Officer, effective as of February 26, 2026. At the time of the Original Report, the Compensation and Human Capital Committee (the “Committee”) of the Company’s Board of Directors had not made a determination regarding any compensation adjustments in connection with Mr. Kennedy’s appointment as the Company’s Chief Financial Officer. In recognition of Mr. Kennedy’s expanded responsibilities in assuming the additional role of Chief Financial Officer, on April 20, 2026, the Committee approved (i) an award of 24,134 restricted stock units (the “RSUs”), of which one-third will vest on April 6, 2027, and one-twelfth will vest quarterly thereafter and (ii) an award of 24,134 restricted stock units subject to target achievement of certain performance-based vesting conditions (the “PRSUs”), which will be eligible to vest between 0% to 200% of such target number, subject to the achievement of performance-based vesting conditions over the 2026 and 2027 performance periods, and additional time-based vesting requirements, in each case subject to Mr. Kennedy’s continued services to the Company on each vesting date, except as otherwise provided in Mr. Kennedy’s existing Change of Control and Severance Agreement. The RSUs and PRSUs were granted under the Company’s 2024 Equity Incentive Plan and are in addition to the equity awards previously granted to Mr. Kennedy in connection with his service as Chief Operating Officer. Mr. Kennedy’s annual base salary of $613,000 and annual target bonus opportunity of 75% of his base salary remain unchanged.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    CAREDX, INC.
    Date: April 23, 2026
    By:
     
    /s/ JOHN HANNA
     
    John W. Hanna
     
    President, Chief Executive Officer and Director


    Get the next $CDNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/6/2026$26.00Buy → Hold
    Craig Hallum
    8/26/2025Mkt Perform
    William Blair
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    More analyst ratings

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kennedy Keith

    4 - CareDx, Inc. (0001217234) (Issuer)

    4/22/26 4:05:13 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form 4 filed by Hanna John Walter Jr

    4 - CareDx, Inc. (0001217234) (Issuer)

    4/20/26 4:53:54 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form 4 filed by Hanna John Walter Jr

    4 - CareDx, Inc. (0001217234) (Issuer)

    4/16/26 4:05:05 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing

    AlloSeq Nano delivers rapid, high‑resolution HLA and ABO genotyping in a single assay through a streamlined, long‑read workflow designed for transplant and donor typing laboratories. CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026. AlloSeq Nano is an innovation developed by CareDx to deliver high‑resol

    4/20/26 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results

    Transaction Expected to Sharpen CareDx's Focus on Core Precision Medicine Testing Services and Patient and Digital Solutions, Improve Financial Flexibility, Simplify Operating Model, and Support AEBITDA Margin Expansion Expects First Quarter Testing Services Revenue Growth of Approximately 48% Year Over Year, Testing Volume Growth of Approximately 17% Year-Over-Year CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that it has entered into a definitive agreement to dives

    4/15/26 4:30:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report First Quarter 2026 Financial Results on April 28, 2026

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, April 28, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone,

    4/14/26 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    SEC Filings

    View All

    Amendment: CareDx Inc. filed SEC Form 8-K: Leadership Update

    8-K/A - CareDx, Inc. (0001217234) (Filer)

    4/23/26 4:12:41 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form 144 filed by CareDx Inc.

    144 - CareDx, Inc. (0001217234) (Subject)

    4/16/26 4:12:23 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Inc. filed SEC Form 8-K: Regulation FD Disclosure, Entry into a Material Definitive Agreement, Results of Operations and Financial Condition

    8-K - CareDx, Inc. (0001217234) (Filer)

    4/16/26 6:05:59 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CareDx downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded CareDx from Buy to Hold and set a new price target of $26.00

    1/6/26 9:07:34 AM ET
    $CDNA
    Medical Specialities
    Health Care

    William Blair initiated coverage on CareDx

    William Blair initiated coverage of CareDx with a rating of Mkt Perform

    8/26/25 8:17:26 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

    1/15/25 7:29:19 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Financials

    Live finance-specific insights

    View All

    CareDx to Report First Quarter 2026 Financial Results on April 28, 2026

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, April 28, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone,

    4/14/26 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference ca

    2/10/26 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

    Company to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ET Investor webcast will feature the clinical validation data and review commercial launch timeline CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 4-7, 2026, in Salt Lake City, U

    2/3/26 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/14/24 5:13:57 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/8/24 2:34:10 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/5/24 6:07:26 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Leadership Updates

    Live Leadership Updates

    View All

    CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

    Kennedy brings seven years of public company CFO experience CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective February 26, 2026. Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contrac

    2/24/26 5:15:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

    Renowned Transplant Clinician to Lead CareDx Global Medical Affairs CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of experience in clinical transplantation, including senior leadership roles at Stanford University and the University of Pittsburgh Medical Center. He is board certified in Heart Failure/Cardiac Transplantation

    10/27/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

    CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the appointment of Suresh Gunasekaran to its Board of Directors. Suresh currently serves as President and Chief Executive Officer at UCSF Health, an internationally renowned health system for providing highly specialized and innovative care, including solid organ and bone marrow transplantation. Suresh has more than 20 years of executive leadership experience in healthcare administration and information technology, with a proven track record of driving operational

    10/22/25 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care